DOCSLIB.ORG

ERANSKINA ANEXO I+G Proiektuen, Azterlan Klinikoen Eta Argitalpen Zientifikoen Zerrenda Proyectos De I+D, Estudios Clínicos Y Lista De Publicaciones Científicas 1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ERANSKINA ANEXO I+G Proiektuen, Azterlan Klinikoen Eta Argitalpen Zientifikoen Zerrenda Proyectos De I+D, Estudios Clínicos Y Lista De Publicaciones Científicas 1 2018ko MEMORIA 2018 I+G+B jarduera Euskal Osasun Sistema Publikoan Actividad de I+D+i del Sistema Sanitario Público Vasco ERANSKINA ANEXO I+G proiektuen, azterlan klinikoen eta argitalpen zientifikoen zerrenda Proyectos de I+D, estudios clínicos y lista de publicaciones científicas 1. 2018an jarduneko proiektu lehiakorrak Proyectos competitivos activos en 2018 4 Índice de contenido 2. 2018an jarduneko proiektu lehiakorrak Eduki- Estudios clínicos activos en 2018 52 aurkibidea 3. Euskal osasun sistema publikoaren 2018ko argitalpenak Publicaciones 2018 del sistema sanitario público vasco 172 MEMORIA 2018 - ERANSKINA/ANEXO / 3 2018. urteari dagokion inbentario Se incluye en el presente inventario honetan, honako hauek ageri dira: relativo a 2018 las siguientes: • 2018ko jarduneko ikerketa-proiektuak, lehia-erregimeneko • Los proyectos de investigación activos durante el 2018, deialdien bidez eskuratuak eta Euskal Osasun Sistema obtenidos a través de convocatorias competitivas y que se Publikoan gauzatzen direnak. ejecutan en el Sistema Sanitario Público Vasco. Ordenado por centro y anualidad. • 2018ko jarduneko azterlan klinikoak; barne hartzen ditu medikamentuen eta produktu sanitarioen azterlan klinikoak, • Los estudios clínicos activos en 2018, incluye ensayos baimendu osteko azterlanak eta behaketa-motako clínicos de medicamentos y productos sanitarios, estudios azterlanak. Azterlan horietako asko hainbat zentrotan post-autorización y estudios observacionales. Muchos de gauzatzen dituzte aldi berean, Osakidetzaren zerbitzuetako estos estudios son multicéntricos y se ejecutan en varias de zenbait erakundetan. las organizaciones de servicios de Osakidetza. Ordenado por código identificativo y anualidad. • 2018ko argitalpen zientifikoak, hala nola honako hauek: abstract of Item Published, article, correction, editorial • Publicaciones científicas de 2018, entre las que se incluyen material, letter, meeting abstract eta review. los abstract of Item Published, article, correction, editorial material, letter, meeting abstract y review. MEMORIA 2018 - ERANSKINA/ANEXO / 4 2018an jarduneko proiektu lehiakorrak Proyectos competitivos activos en 2018 01 KODEA GAUZATZE ZENTROA IZENBURUA FINANTZA ERAKUNDEA URTEA CÓDIGO CENTRO DE EJECUCIÓN TÍTULO ENTIDAD FINANCIADORA AÑO RTC-2014-1444-1 CVTTH H2-HLA, HERRAMIENTA PARA EL TIPADO DE ALTA RESOLUCIÓN MINISTERIO DE ECONOMÍA, INDUSTRIA Y 2014 Y DE ALTA CAPACIDAD DE ANTÍGENOS HLA COMPETITIVIDAD FDEXEUS15/001 CVTTH OPTIMIZACION DE METODOS PARA LA PRESERVACION DE LA FUNDACION DEXEUS 2015 FERTILIDAD MASCULINA EN PACIENTES PEDIATRICOS CON CANCER 2016111140 CVTTH MODELAR INMUNODEFICIENCIAS RELACIONADAS CON DEPARTAMENTO DE SALUD 2016 DEFECTOS EN LAS CELULAS NK EN UNA PLACA PETRI/ MODELLINH HUMAN NATURAL KILLER CELL DEFICIENCIES IN THE PETRI DISH UE/2016/TRANSPOSE CVTTH TRANSFUSION AND TRANSPLANTATION: PROTECTION AND COMISION EUROPEA - DG SANCO 2016 SELECTION OF DONORS FSALUD17/004 CVTTH OPTIMIZACION DE METODOS PARA LA PRESERVACION DE LA FUNDACION MERCK SALUD 2017 FERTILIDAD MASCULINA EN PACIENTES PEDIATRICOS CON CANCER O SINDROMES GENETICOS RTC-2017-6000-1 CVTTH IPSC ALOGÉNICAS A PARTIR DE UNIDADES DE SCU BANC DE SANG E TEIXITS 2017 HOMOZIGOTAS PARA HAPLOTIPOS DE ELEVADA PREVALENCIA 2018222038BIOEF CVTTH PAPEL DE LAS CELULAS NK EN EL TRASPLANTE DE DEPARTAMENTO DE SALUD 2018 PRECURSORES HEMATOPOYETICOS AUTOLOGO EN EL TRATAMIENTO DE CANCER Y ENFERMEDADES RARAS FII18/003 CVTTH GENERACION DE CELULAS NKS QUE EXPRESAN RECEPTORES FUNDACION INOCENTE INOCENTE 2018 QUIMERICOS DE ANTIGENOS (CARS) PARA TRATAMIENTO DE CANCER PEDIATRICO REFRACTARIO UE/2012/DISCHARGE DEPARTAMENTO DE SALUD DIAGNOSTIC IMAGING STRATEGIES FOR CORONARY COMISION EUROPEA - DG RESEARCH 2012 ANGIOGRAPHY IN PATIENTS WITH STABLE ANGINA: COMPARATIVE EFFECTIVENESS RESEARCH OF EXISTING TECHNOLOGIES (DISCHARGE) - A PRAGMATIC RANDOMISED CONTROLLED TRIAL PI15/01752 DEPARTAMENTO DE SALUD CRONODIETA, POLIMORFISMOS DE GENES REGULADORES ISCIII INSTITUTO DE SALUD CARLOS III 2015 DEL RELOJ CIRCADIANO, CAMBIO DE PESO Y OBESIDAD EN EL ESTUDIO PROSPECTIVO EUROPEO SOBRE NUTRICION Y CANCER (EPIC ESPAÑA) MEMORIA 2018 - ERANSKINA/ANEXO / 5 2018an jarduneko proiektu lehiakorrak Proyectos competitivos activos en 2018 01 KODEA GAUZATZE ZENTROA IZENBURUA FINANTZA ERAKUNDEA URTEA CÓDIGO CENTRO DE EJECUCIÓN TÍTULO ENTIDAD FINANCIADORA AÑO UE/2015/EUNETHTA- DEPARTAMENTO DE SALUD HEALTH TECHNOLOGY ASSESSMENT COOPERATION COMISION EUROPEA - DG SANCO 2015 JA3 UE/2015/I-MOVE-PLUS DEPARTAMENTO DE SALUD I-MOVE+ INTEGRATED MONITORING OF VACCINES EFFECTS COMISION EUROPEA - HORIZON 2020 2015 IN EUROPE: A PLATFOTM TO MEASURE AND COMPARE EFFECTIVENESS AND IMPACT OF INFLUENZA AND PNEUMOCOCCAL VACCINES AND VACCINATION STRATEGIES IN THE ELDERLY PI16/01187 DEPARTAMENTO DE SALUD DESIGUALDADES SOCIOECONOMICAS Y MEDIOAMBIENTALES ISCIII INSTITUTO DE SALUD CARLOS III 2016 EN LA DISTRIBUCION GEOGRAFICA DE LA MORTALIDAD EN EL PAIS VASCO Y EN SUS TRES CAPITALES (1996-2015): MEDEA 3 PAIS VASCO UE/2016/EUROLINKCAT DEPARTAMENTO DE SALUD EUROLINKCAT: ESTABLISHING A LINKED EUROPEAN COHORT COMISION EUROPEA - HORIZON 2020 2016 OF CHILDREN WITH CONGENITAL ANOMALIES UE/2016/H2020/ DEPARTAMENTO DE SALUD MEANINGFUL INTEGRATION OF DATA, ANALYTICS AND COMISION EUROPEA - HORIZON 2020 2016 MIDAS-BD- SERVICES UE/2016/POCTEFA/ DEPARTAMENTO DE SALUD DESARROLLO DE UNA SOLUCIÓN PIONERA DE AUTOCONTROL POCTEFA-INTERREG 2016 TESTACOS EN ANIMALES VIVOS PARA MINIMIZAR LA PRESENCIA DE RESIDUOS DE ANTIBIÓTICOS EN LA CADENA ALIMENTARIA DEL ÁREA TRANSFRONTERIZA ESPAÑA-FRANCIA 2017111120BD DEPARTAMENTO DE SALUD ESTUDIO PILOTO SOBRE LA EFECTIVIDAD DE UNA DEPARTAMENTO DE SALUD 2017 INTERVENCION TEMPRANA MULTIMODAL PARA LA PREVENCION DE LA DEMENCIA Y CUIDADO DE LA SALUD COGNITIVA (GOIZ-ZAINDU) UE/17/CHAFEA/JA/ DEPARTAMENTO DE SALUD JOINT ACTION ON HEALTH EQUITY EUROPE-JA-HEE COMISION EUROPEA - DG SANCO 2017 JA-HEE UE/18/ERASMUS/ DEPARTAMENTO DE SALUD VALUES IN DOING ASSESSMENTS OF HEALTHCARE COMISION EUROPEA 2018 VALIDATE-2 TECHNOLOGIES 2012111032 E.U. ENFERMERIA VITORIA CARACTERISTICAS RESILIENTES Y DE AFRONTAMIENTO DEPARTAMENTO DE SALUD 2012 PREDICTORAS DE UN MEJOR AJUSTE Y CALIDAD DE VIDA EN PERSONAS TRATADAS CON QUIMIOTERAPIA SISTEMICA AMBULATORIA MEMORIA 2018 - ERANSKINA/ANEXO / 6 2018an jarduneko proiektu lehiakorrak Proyectos competitivos activos en 2018 01 KODEA GAUZATZE ZENTROA IZENBURUA FINANTZA ERAKUNDEA URTEA CÓDIGO CENTRO DE EJECUCIÓN TÍTULO ENTIDAD FINANCIADORA AÑO UE/2016/POCTEFA/ EMERGENCIAS RED DE COOPERACIÓN TRANSFRONTERIZA EN LA GESTIÓN POCTEFA-INTERREG 2016 HELINET CONJUNTA DE RIESGOS Y MISIONES DE AYUDA MUTUA EN SITUACIONES DE URGENCIA, EMERGENCIA, RESCATE Y CATÁSTROFES, MEDIANTE LA POTENCIACIÓN DE LA UTILIZACIÓN DE HELICÓPTEROS 2018222011BD EMERGENCIAS DETERMINACION DE VALORES DE OXIMETRIA CEREBRAL PARA DEPARTAMENTO DE SALUD 2018 LA PREDICCION DE LOS RESULTADOS DE INTERVENCION EN PACIENTES EN PARADA CARDIORESPIRATORIA EXTRAHOSPITALARIAS UE/18/POCTEP/EMS EMERGENCIAS WHEN EMS (EMERGENCY MEDICAL SYSTEM) ERASE BORDERS ASSOCIATION OF EUROPEAN BORDER 2018 REGIONS (AEBR) MINECO15/1101 FUNDACION VASCA DE BIGDATIUS: USO DE DATOS CLINICOS ANTE NUEVOS MINISTERIO DE ECONOMÍA, INDUSTRIA Y 2015 INNOVACION E INVESTIGACION ESCENARIOS TECNOLOGICOS Y CIENTIFICOS (BIG DATA). COMPETITIVIDAD SANITARIAS - BIOEF OPORTUNIDADES E IMPLICACIONES JURIDICAS UE/2015/REFBIOII FUNDACION VASCA DE RED TRANSFRONTERIZA DE INVESTIGACIÓN BIOMÉDICA DE POCTEFA-INTERREG 2015 INNOVACION E INVESTIGACION LOS PIRINEOS 2. HACIA LA TRANSFERENCIA EFECTIVA DE SANITARIAS - BIOEF RESULTADOS DE LA I+D BIOMÉDICA Y SU VALORIZACIÓN EN EL ESPACIO PIRINEOS KK-2016/00026 FUNDACION VASCA DE BG 2016. INVESTIGACIÓN COLABORATIVA EN MEDIDINA DE DEPARTAMENTO DE DESARROLLO 2016 INNOVACION E INVESTIGACION PRECISIÓN Y BIOMARCADORES ECONÓMICO E INFRAESTRUCTURAS SANITARIAS - BIOEF UE/2016/H2020/ FUNDACION VASCA DE MEANINGFUL INTEGRATION OF DATA, ANALYTICS AND COMISION EUROPEA - HORIZON 2020 2016 MIDAS-BD- INNOVACION E INVESTIGACION SERVICES SANITARIAS - BIOEF UE/2016/PICCOLO- FUNDACION VASCA DE MULTIMODAL HIGHLY-SENSITIVE PHOTONICS ENDOSCOPE FOR COMISION EUROPEA - HORIZON 2020 2016 BIOEF INNOVACION E INVESTIGACION IMPROVED IN-VIVO COLON CANCER DIAGNOSIS AND CLINICAL SANITARIAS - BIOEF DECISION SUPPORT KK-2017/00084-BIOEF FUNDACION VASCA DE BG17 - PREVENCIÓN, DIAGNÓSTICO, INVESTIGACIÓN Y NUEVAS DEPARTAMENTO DE DESARROLLO 2017 INNOVACION E INVESTIGACION LINEAS TERAPÉUTICAS PARA ENFERMEDADES RARAS EN EL ECONÓMICO E INFRAESTRUCTURAS SANITARIAS - BIOEF MARCO DE LA CAPV 2018222007 FUNDACION VASCA DE HACIA UN DIAGNOSTICO Y TRATAMIENTO PERSONALIZADO DEPARTAMENTO DE SALUD 2018 INNOVACION E INVESTIGACION DE PATOLOGIAS METABOLICAS CONGENITAS EN LA CAPV SANITARIAS - BIOEF (NOTRARE) MEMORIA 2018 - ERANSKINA/ANEXO / 7 2018an jarduneko proiektu lehiakorrak Proyectos competitivos activos en 2018 01 KODEA GAUZATZE ZENTROA IZENBURUA FINANTZA ERAKUNDEA URTEA CÓDIGO CENTRO DE EJECUCIÓN TÍTULO ENTIDAD FINANCIADORA AÑO KK-2018/00032-BIOEF FUNDACION VASCA DE SENDANEU - SMART-ANALYTICS PARA EL APOYO AL DEPARTAMENTO DE DESARROLLO 2018 INNOVACION E INVESTIGACION DIAGNOSTICO Y TRATAMIENTO DE ENFERMEDADES ECONÓMICO E INFRAESTRUCTURAS SANITARIAS - BIOEF NEURODEGENERATIVAS KK-2018/00054-BIOEF FUNDACION VASCA DE BG18 - MEDICINA PERSONALIZADA: DESARROLLO DE DEPARTAMENTO DE DESARROLLO 2018 INNOVACION E INVESTIGACION HERRAMIENTAS DE DIAGNOSIS Y TERAPIAS EN CANCER ECONÓMICO E INFRAESTRUCTURAS SANITARIAS - BIOEF ZL-2018/00539-BIOEF FUNDACION VASCA DE EMIX - EUSKADIKO MINBIZIAREN IKERKETA SAREA (FASE
Load more

Recommended publications
  • Ectrims Meeting November 2015
    SUPPLEMENT TO HIGHLIGHTS FROM THE ECTRIMS MEETING NOVEMBER 2015 Ocrelizumab May Reduce Disability Progression in People With Primary Progressive MS Data support the hypothesis that B cells are central to the underlying biology of MS. BARCELONA—In people with primary progressive Overall, the incidence of adverse events associated multiple sclerosis (MS), treatment with ocrelizumab may with ocrelizumab was similar to that of placebo. The most significantly reduce the progression of clinical disability common adverse events were mild-to-moderate infusion- sustained for at least 12 weeks, compared with placebo, related reactions. The incidence of serious adverse events according to results from a pivotal phase III study presented associated with ocrelizumab, including serious infections, at the 31st Congress of the European Committee for Treat- was also similar to that of placebo. ment and Research in Multiple Sclerosis (ECTRIMS). In the “People with the primary progressive form of MS typi- study, which is called ORATORIO, clinical disability was cally experience symptoms that continuously worsen after measured by the Expanded Disability Status Scale (EDSS). the onset of their disease, and there are no approved treat- Ocrelizumab is an investigational, humanized mono- ments for this debilitating condition,” said Sandra Horn- clonal antibody designed to selectively target CD20-posi- ing, MD, Chief Medical Officer and Head of Global Product tive B cells. CD20-positive B cells are a type of immune cell Development for Genentech, the developer
    [Show full text]
  • NP 2013.Docx
    LISTE INTERNATIONALE DES NOMS PROTÉGÉS (également disponible sur notre Site Internet : www.IFHAonline.org) INTERNATIONAL LIST OF PROTECTED NAMES (also available on our Web site : www.IFHAonline.org) Fédération Internationale des Autorités Hippiques de Courses au Galop International Federation of Horseracing Authorities 15/04/13 46 place Abel Gance, 92100 Boulogne, France Tel : + 33 1 49 10 20 15 ; Fax : + 33 1 47 61 93 32 E-mail : [email protected] Internet : www.IFHAonline.org La liste des Noms Protégés comprend les noms : The list of Protected Names includes the names of : F Avant 1996, des chevaux qui ont une renommée F Prior 1996, the horses who are internationally internationale, soit comme principaux renowned, either as main stallions and reproducteurs ou comme champions en courses broodmares or as champions in racing (flat or (en plat et en obstacles), jump) F de 1996 à 2004, des gagnants des neuf grandes F from 1996 to 2004, the winners of the nine épreuves internationales suivantes : following international races : Gran Premio Carlos Pellegrini, Grande Premio Brazil (Amérique du Sud/South America) Japan Cup, Melbourne Cup (Asie/Asia) Prix de l’Arc de Triomphe, King George VI and Queen Elizabeth Stakes, Queen Elizabeth II Stakes (Europe/Europa) Breeders’ Cup Classic, Breeders’ Cup Turf (Amérique du Nord/North America) F à partir de 2005, des gagnants des onze grandes F since 2005, the winners of the eleven famous épreuves internationales suivantes : following international races : Gran Premio Carlos Pellegrini, Grande Premio Brazil (Amérique du Sud/South America) Cox Plate (2005), Melbourne Cup (à partir de 2006 / from 2006 onwards), Dubai World Cup, Hong Kong Cup, Japan Cup (Asie/Asia) Prix de l’Arc de Triomphe, King George VI and Queen Elizabeth Stakes, Irish Champion (Europe/Europa) Breeders’ Cup Classic, Breeders’ Cup Turf (Amérique du Nord/North America) F des principaux reproducteurs, inscrits à la F the main stallions and broodmares, registered demande du Comité International des Stud on request of the International Stud Book Books.
    [Show full text]
  • I. Canadian Expeditionary Force
    . mpliPing (ISSUED WITH MILITIA ORDERS, 1917.) I. Canadian Expeditionary Force e Pir 2nd Pioneer Battalion Nominal Roll of Officers, Non -Commissioned Officers and Men. EMBARKATION. Port: Halifax, N.S. Ship: S.S. "Orduna." 3m -10-17 6th, 1915. 593 -2-29 Date: December 111111111111ftw - 2nd PIONEER BATTALION a . , TAKEN ON STRENGTH. of Next of Kin. ' Country of No. Rank. Name. ' Former Corps. Name of Next of Kin. Address az Birth. Place. Date. á Regimental Lieut. -Colonel Davis, William Mahlon Can. Mil Davis, Mrs. Catharine S c/o John A. McKay, Windsor, Ont Canada Quebec Dec. 3, 1915. Major Bodwell, Howard Lionel .. 72nd Regt Bodwell, Mrs. Dulcie Margaret c/o Miss C. Marshall Margaret Smith, Mathews Ave., Shaughnessy Heights, B.C. Canada Quebec Dec. 3, 1915. Captain Allen, Carlton Woodford Can. Eng. and S. A Allen, Mrs. C. W Dominion Bank, 73 Cornhill, London, E.C., Eng . Canada Quebec , . Oct. 3, 1915. Captain Brown, Frederick Midwood O.T.0 Brown, Mrs. Grace Isobel cm A. F. Clayford, Three Rivers, P.Q England Sydney Mines Nov. 30, 1915. Captain Caldwell, William Ronald C. of G Caldwell, Mrs. Elsie Ross Carleton Place, Ont Canada Quebec Dec. 4, 1915. Hon. Captain Clarke, H. B 93rd Regt .. Quebec Dec. 4, 1915. Captain Dennis, Henry Joseph , C. of G Not stated Not stated ,.:.. Canada Captain Gendron, Fernand Edouard Can. Eng Gendron, Mrs. F. H 111 Champlain Ave., Hull, P.Q Canada Quebec Dec. 3, 1915. Captain Gibson, Leonard Can. Eng Gibson, George Fawcett Osborne House, North Cliff, Scarborough, Yorks, Eng England quebec - Dec. 3, 1915. Captain McKay, David John C.A.M.0 McKay, Mrs.
    [Show full text]
  • Monoclonal Antibodies As Neurological Therapeutics
    pharmaceuticals Review Monoclonal Antibodies as Neurological Therapeutics Panagiotis Gklinos 1 , Miranta Papadopoulou 2, Vid Stanulovic 3, Dimos D. Mitsikostas 4 and Dimitrios Papadopoulos 5,6,* 1 Department of Neurology, KAT General Hospital of Attica, 14561 Athens, Greece; [email protected] 2 Center for Clinical, Experimental Surgery & Translational Research, Biomedical Research Foundation of the Academy of Athens (BRFAA), 11527 Athens, Greece; [email protected] 3 Global Pharmacovigilance, R&D Sanofi, 91385 Chilly-Mazarin, France; vid.stanulovic@sanofi.com 4 1st Neurology Department, Aeginition Hospital, National and Kapodistrian University of Athens, 11521 Athens, Greece; [email protected] 5 Laboratory of Molecular Genetics, Hellenic Pasteur Institute, 129 Vasilissis Sophias Avenue, 11521 Athens, Greece 6 Salpetriere Neuropsychiatric Clinic, 149 Papandreou Street, Metamorphosi, 14452 Athens, Greece * Correspondence: [email protected] Abstract: Over the last 30 years the role of monoclonal antibodies in therapeutics has increased enormously, revolutionizing treatment in most medical specialties, including neurology. Monoclonal antibodies are key therapeutic agents for several neurological conditions with diverse pathophysio- logical mechanisms, including multiple sclerosis, migraines and neuromuscular disease. In addition, a great number of monoclonal antibodies against several targets are being investigated for many more neurological diseases, which reflects our advances in understanding the pathogenesis of these
    [Show full text]
  • A Tale of the Apocryphal Axe: Repair, Reconstruction, and the Implied License in Intellectual Property Law
    Maurer School of Law: Indiana University Digital Repository @ Maurer Law Articles by Maurer Faculty Faculty Scholarship 1999 A Tale of the Apocryphal Axe: Repair, Reconstruction, and the Implied License in Intellectual Property Law Mark D. Janis Indiana University Maurer School of Law, [email protected] Follow this and additional works at: https://www.repository.law.indiana.edu/facpub Part of the Intellectual Property Law Commons Recommended Citation Janis, Mark D., "A Tale of the Apocryphal Axe: Repair, Reconstruction, and the Implied License in Intellectual Property Law" (1999). Articles by Maurer Faculty. 542. https://www.repository.law.indiana.edu/facpub/542 This Article is brought to you for free and open access by the Faculty Scholarship at Digital Repository @ Maurer Law. It has been accepted for inclusion in Articles by Maurer Faculty by an authorized administrator of Digital Repository @ Maurer Law. For more information, please contact [email protected]. A TALE OF THE APOCRYPHAL AXE: REPAIR, RECONSTRUCTION, AND THE IMPLIED LICENSE IN INTELLECTUAL PROPERTY LAW MARK D. JANIS* I. THE EXHAUSTION OF RIGHTS AND THE REPAIR- RECONSTRUCTION PROBLEM ................................ 429 A. Exhaustion of Intellectual Property Rights ............... 431 B. The Repair-ReconstructionProblem: Origins, Evolution, Confusion ........................................... 436 1. The Ambivalence of Wilson v. Simpson ............ 437 2. A "Pandora'sFlock "and Two Contradictory Notions of Spentness: The Aro I Case ..................... 443 a. Aro I "sRejection of a Multifactor Approach to Repair-Reconstruction......................... 444 b. Aro I's "Spentness" Standard.................. 446 II. THE HEART, THE SOUL, AND THE PARTS OF THE WHOLE: THE FAILURE OF SPENTNESS AS A STANDARD FOR REPAIR- RECONSTRUCTION ......................................... 448 A. The Soul of the Invention: The Metaphysics of Machine Identity .............................................
    [Show full text]
  • Q3 Tnt Submission Revised Sheet.Xlsx
    Recruitment REC No Research Title Local Target Active Status Close Date A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (erlotinib) Following 06/MRE01/102 31/03/2010 Complete Tumor Resection with or without Adjuvant 10 Closed - follow up complete Chemotherapy in Patients with Stage IB-IIIA Non small Cell Lung Carcinoma who have N BH21260- A randomised, controlled, open-label, multi-centre, parallel-group study to assess all-cause mortality and 08/H0502/132 14/10/2011 cardiovascular morbidity in patients with chronic kidney 9 Closed - follow up complete disease on dialysis and those not on renal replacement therapy under treatment wit Y 09/H0706/22 14/12/2013 Aliskiren vs enalapril in chronic heart failure 4 Closed - follow up complete Y An OpenLabel, MultiCenter, Single Arm Study to Evaluate the Safety and Tolerability of Intravenous Zanamivir in the 09/H0802/125 27/01/2017 1 Closed - follow up complete Treatment of Hospitalised Adult, Adolescent and Paediatric Subjects with Confirmed Influenza Infection N A Randomized, Double-Blind, Parallel-Group, Placebo- Controlled Study to Assess the Efficacy, Safety, Tolerability, 12/SC/0527 26/02/2014 2 Closed - follow up complete and Pharmacokinetics of BIIB033 in Subjects With First Episode of Acute Optic Neuritis N A double-blind randomized, placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 Antigen -Specific 07/MRE08/40 31/05/2012 Cancer immunotherapeutic as adjuvant therapy in patients 12 Closed - in follow up
    [Show full text]
  • WO 2016/025911 Al 18 February 2016 (18.02.2016)
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/025911 Al 18 February 2016 (18.02.2016) (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 9/14 (2006.01) A61K 9/16 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 38/00 (2006.01) A61K 9/19 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 39/00 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, PCT/US20 15/045402 KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (22) International Filing Date: MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, 14 August 2015 (14.08.2015) PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (25) Filing Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 62/037,492 14 August 2014 (14.08.2014) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicants: BROWN UNIVERSITY [US/US]; 47 TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, George Street, Providence, RI 02912 (US).
    [Show full text]
  • Table of Contents
    BEYOND THE BORN GLOBAL: UNDERSTANDING THE INTERNATIONALISATION PROCESS OF BIOTECHNOLOGY VENTURES Lisa Jane Hewerdine Business School University of Adelaide August 2008 ABSTRACT BEYOND THE BORN GLOBAL: Understanding the Internationalisation Process of Biotechnology Ventures The past decade has seen a surge of interest in ‘born global’ firms which internationalise rapidly following their inception. While born global internationalisation paths are commonly associated with high tech firms, there has been some limited research suggesting that biotech ventures do not fit this model. My aim, therefore, was to contribute to international business research by investigating whether biotech firms internationalise as is suggested by born global scholars. Accordingly, my research focused on examining how the internationalisation of these small firms with radical innovations might best be explained. My research proceeded by means of a comparative case study of four Australian biotech companies, with their internationalisation histories forming the focal unit of analysis. The first contribution resulting from my cross-case analysis is to show that oversimplified measures of firm inception have led to ‘conceptual stretching’ of the born global category. This does not imply that born globals do not exist; rather; I argue that greater care needs to be applied when measuring inception. Ultimately, biotech firms do not fit easily into the born global category because the lengthy innovation process they undergo means they are likely to have strong pre-organisational roots extending far beyond their incorporation date. This pre-organisational history needs to be factored in because of its effects on firm internationalisation. i My second contribution is to suggest a driver for internationalisation that to date has not been included in existing research into high tech firms: namely, the influence of the innovation process.
    [Show full text]
  • Company Data, Credit Suisse Analysis Slide 4 September 2013 Our Top-10 Sound Bites/Observation/Questions/Focal Points for the Conference(Cont.)
    Global Biotechnology and Pharmaceuticals 24th September 2013 Multiple Sclerosis – ECTRIMS 2013 Prep-Pack It’s A Revolution! But Just How Big? Research Analysts Ravi Mehrotra, Ph.D. 212-325-3487 [email protected] EU Pharma Team Koon Ching, Ph.D. Vamil Divan Lee Kalowski 44 20 7888 0304 212 325 6286 212 538 5394 212-325-3777 [email protected] [email protected] [email protected] [email protected] Ari Jahja Ronak Shah, Pharm.D., CFA Anuj Shah Jason Kantor 212 325 0767 212 325 9799 212 325 6931 415 249 7942 [email protected] [email protected] [email protected] [email protected] DISCLOSURE APPENDIX CONTAINS IMPORTANT DISCLOSURES, ANALYST CERTIFICATIONS, INFORMATION ON TRADE ALERTS, ANALYST MODEL PORTFOLIOS AND THE STATUS OF NON-U.S ANALYSTS. U.S. Disclosure: Credit Suisse does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Evolution AND Revolution! As a humorous point/observation, we find the titles of the two Biogen sponsored symposium to be held at ECTRIMS very interesting: 10/2 17.15 “Biogen Idec: Reinventing MS care – Evolution” and 10/3 07.45 “Biogen Idec: Reinventing MS care – Revolution”. Umm, we wonder where they got that inspiration from… Slide 2 September 2013 Table of Contents: It’s A Revolution! At ECTRIMS 2013, we are focused on these particular areas: 1) Dynamics of Tecfidera’s launch - Warehoused vs.
    [Show full text]
  • 2020 International List of Protected Names
    INTERNATIONAL LIST OF PROTECTED NAMES (only available on IFHA Web site : www.IFHAonline.org) International Federation of Horseracing Authorities 03/06/21 46 place Abel Gance, 92100 Boulogne-Billancourt, France Tel : + 33 1 49 10 20 15 ; Fax : + 33 1 47 61 93 32 E-mail : [email protected] Internet : www.IFHAonline.org The list of Protected Names includes the names of : Prior 1996, the horses who are internationally renowned, either as main stallions and broodmares or as champions in racing (flat or jump) From 1996 to 2004, the winners of the nine following international races : South America : Gran Premio Carlos Pellegrini, Grande Premio Brazil Asia : Japan Cup, Melbourne Cup Europe : Prix de l’Arc de Triomphe, King George VI and Queen Elizabeth Stakes, Queen Elizabeth II Stakes North America : Breeders’ Cup Classic, Breeders’ Cup Turf Since 2005, the winners of the eleven famous following international races : South America : Gran Premio Carlos Pellegrini, Grande Premio Brazil Asia : Cox Plate (2005), Melbourne Cup (from 2006 onwards), Dubai World Cup, Hong Kong Cup, Japan Cup Europe : Prix de l’Arc de Triomphe, King George VI and Queen Elizabeth Stakes, Irish Champion North America : Breeders’ Cup Classic, Breeders’ Cup Turf The main stallions and broodmares, registered on request of the International Stud Book Committee (ISBC). Updates made on the IFHA website The horses whose name has been protected on request of a Horseracing Authority. Updates made on the IFHA website * 2 03/06/2021 In 2020, the list of Protected
    [Show full text]
  • The Future of MS Treatments
    The future of MS Treatments 1 Abstract Introduction. There are not many conditions in which the last few decades have brought such a major change in the landscape of treatments as is the case of multiple sclerosis (MS). A number of disease modifying treatments (DMTs) are presently available for the treatment of the inflammatory phase of this disabling disease; however, the need for treating neurodegeneration and halting the progression of disability is still unmet. Areas covered: In this paper we review the available information on existing and emerging DMTs and we discuss their place within the context of different treatment strategies in MS, Expert Commentary: The future of MS treatments should include the development of new treatment strategies tackling disease progression, together with a better understanding of the side-effects and the best sequential strategy of implementation of available and emerging drugs. Keywords Multiple sclerosis, immunomodulation, monoclonal antibodies, remyelination, repurposing 2 Introduction Multiple sclerosis (MS) is a chronic, immune-mediated condition causing inflammation and neurodegeneration in the brain and spinal cord and the most common non-traumatic cause of neurological disability in young people in the western world [1]. In most patients, MS initially has a relapsing–remitting course (RRMS) with bouts of inflammation (relapses) and periods of remission. In the majority of people with MS, the relapsing course will later be followed by a secondary progressive phase (SPMS) [2]. In around 15% of cases, the disease progresses from the beginning with a primary progressive course without superimposed relapses (PPMS) [2]. More recent classifications put emphasis on the inflammatory activity which can be present at all stages of the disease and can be targeted with disease-modifying treatments (DMTs) [3].
    [Show full text]
  • 09/H0402/92 20080763 Panitumumab Vs C
    Recruitment Recruitment Rec Number Name of Trial Target End Date Trial Status Target met ? 20080763 Panitumumab vs Cetuximab in 09/H0402/92 Colorectal Cancer 10 05/01/2015 Closed - Follow Up Complete Y BO21004 - RO5072759 Safety and Efficacy 09-WSE04-55 Chemo Combo in untreated CLL 5 01/04/2022 Closed - In Follow Up Y Phase 3 Study-Tivozanib in Patients with 09/H0903/51 Advanced Renal Cell Carcinoma 5 05/01/2015 Closed - Follow Up Complete N LDK378-Dose Escalation/Expansion study in 10/MRA00/84 patients with ALK+ tumour 2 31/05/2016 Closed - In Follow Up Y Phase I Study of NY-ESO-1 +AS15 in 10/H0806/106 Melanoma Version 1 4 05/01/2015 Closed - Follow Up Complete N BH21260- Mircera? vs. reference ESAs in CKD 08/H0502/133 patients (SUB STUDY) 10 01/01/2016 Withdrawn N/A R-CHOP vs G-CHOP in previously untreated 11/EM/0225 patients with DLBCL 5 01/02/2018 Closed - In Follow Up N 11/NI/0147 SJM Portico 23-TF EU 12 30/11/2014 Closed - In Follow Up Y A UK Phase IIIB expanded access study of 11/SC/0499 INC424 in myelofibrosis 3 13/07/2015 Closed - Follow Up Complete Y 11/AL/0393 Synta 9090-08 20 04/12/2014 Closed - Follow Up Complete N 12/LO/0806 Aflibercept SQoP (AFLIBC06097) 5 31/12/2015 Closed - In Follow Up Y MASERATI 100 Permacol Collagen Paste 12-LO-0928 Study 10 30/04/2015 Closed - In Follow Up Y SafeHer: Safety study with subcutaneous 12/SC/0139 Trastuzumab in breast cancer 10 23/09/2016 Open N/A Safety and tolerability of ONO-4059 in 12/EM/0204 patients with NHL & CLL 7 15/07/2015 Closed - In Follow Up Y Clinical trial of an investigational
    [Show full text]